Skip to main content
Premium Trial:

Request an Annual Quote

APBiotech Ramps Up Proteomics Product Portfolio

NEW YORK, Dec 7 -- Amersham Pharmacia Biotech is launching two new high-performance protein expression analysis and identification tools, the Ettan DALT II and the Ettan Spot Picker, the company said Thursday.  

AP Biotech has designed the tools to be integrated with all other APBiotech proteomics platforms, including the Ettan MALDI-TOF mass spectrometer, and to form part of a fully integrated 2D-MS proteomics system it plans to launch next year.

  “We plan to link 2D electrophoresis with mass spectrometry in a seamless way, launching software and instrumentation to accomplish this,” Camilla Husebondesson, APBiotech’s marketing director for proteomics, told GenomeWeb.

According to the company, the Ettan DALT II system for 2D electrophoresis is the highest capacity unit available on the market.

“This is the only commercially available system that can analyze 24 cm IPG strips—the longest on the market--in both dimensions,” Husebondesson said. The company’s previous systems were only capable of handling 18 cm strips. According to Husebondesson, the additional length offers that much more area for viewing proteins during analysis, and also offers a significant potential increase in resolution.

Husebondesson said the Ettan Spot Picker is a product of the company’s proven liquid handling station and additional, patent-pending technology. APBiotech claims the system improves the speed and accuracy of transferring selected protein spots to microplates for mass spectrometry identification. The system is fully automated in order to reduce the risk of contamination.

The two products are the newest additions to the company’s growing effort to meet the expanding demands of the proteomics market, Husebondesson said.

  “There is currently an increased focus on protein analysis and enormous growth building up in the scientific community. As a result of that we will ramp up accordingly to meet that demand, but our proteomics efforts should be seen in the context of our whole drug discovery program.”

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.